Jefferies Group’s Cardlytics CDLX Stock Holding History

Jefferies Group’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-746	Closed	-$626K	–	1663
2021 Q3	$626K	Sell	746 -6,351	-89%	-$6.44M	﹤0.01%	1151
2021 Q2	$9.01M	Buy	+7,097	New	+$8.01M	0.06%	297

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jefferies Group's CDLX Position: Q4 2021 in Review

Jefferies Group sold out of Cardlytics (CDLX) in Q4 2021, closing a stake of 746 shares — an estimated $626K sold.

Jefferies Group first reported a position in CDLX in Q2 2021 and held it in 2 quarters. The position peaked at $9.01M in Q2 2021. 163 funds tracked by Wall St. Rank hold CDLX as of Q4 2021.

Jefferies Group reported no remaining Cardlytics position as of Q4 2021 after selling out during the quarter.
Jefferies Group sold 746 Cardlytics shares in Q4 2021, an estimated $626K.
Jefferies Group first reported a position in Cardlytics in Q2 2021 and held it in 2 quarters.
Jefferies Group's Cardlytics position peaked at $9.01M in Q2 2021.
163 funds tracked by Wall St. Rank held Cardlytics as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.